Geographical	O
variations	O
in	O
incidence	O
,	O
management	B:C0376636
and	O
survival	O
of	O
hepatocellular	O
carcinoma	I:C2239176
in	O
a	O
Western	O
country	I:C0454664
.	O

Geographical	O
variations	O
in	O
incidence	O
,	O
management	O
and	O
survival	O
of	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
in	O
a	O
Western	O
country	I:C0454664
.	O

Geographical	O
variations	O
in	O
incidence	O
,	O
management	O
and	O
survival	O
of	O
hepatocellular	O
carcinoma	I:C2239176
in	O
a	O
Western	B:C0454664
country	I:C0454664
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	B:C0376636
,	O
and	O
prognosis	O
of	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	O
samples	I:C2348150
,	O
regional	O
data	O
,	O
or	O
registries	O
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	O
,	O
and	O
prognosis	B:C0033325
of	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	O
samples	I:C2348150
,	O
regional	O
data	O
,	O
or	O
registries	O
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	O
,	O
and	O
prognosis	O
of	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	O
samples	I:C2348150
,	O
regional	O
data	O
,	O
or	O
registries	O
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	O
,	O
and	O
prognosis	O
of	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	O
samples	I:C2348150
,	O
regional	O
data	O
,	O
or	O
registries	O
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	O
,	O
and	O
prognosis	O
of	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	B:C2348150
samples	I:C2348150
,	O
regional	O
data	O
,	O
or	O
registries	O
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	O
,	O
and	O
prognosis	O
of	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	O
samples	I:C2348150
,	O
regional	B:C0205147
data	O
,	O
or	O
registries	O
.	O

Information	O
on	O
the	O
incidence	O
,	O
management	O
,	O
and	O
prognosis	O
of	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
is	O
derived	O
from	O
population	O
samples	I:C2348150
,	O
regional	O
data	O
,	O
or	O
registries	B:C0034975
.	O

Comprehensive	O
national	O
evaluations	B:C0220825
within	O
a	O
given	O
country	O
are	O
lacking	O
.	O

Comprehensive	O
national	O
evaluations	O
within	O
a	O
given	O
country	B:C0454664
are	O
lacking	O
.	O

This	O
study	B:C2603343
aimed	O
to	O
investigate	O
regional	O
variations	O
in	O
hepatocellular	O
carcinoma	I:C2239176
care	O
within	O
France	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
regional	B:C0205147
variations	O
in	O
hepatocellular	O
carcinoma	I:C2239176
care	O
within	O
France	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
regional	O
variations	O
in	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
care	O
within	O
France	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
regional	O
variations	O
in	O
hepatocellular	O
carcinoma	I:C2239176
care	O
within	O
France	B:C0016674
.	O

This	O
observational	B:C1518527
study	I:C1518527
analysed	O
data	O
from	O
French	O
administrative	O
databases	I:C0242356
for	O
more	O
than	O
30,000	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
diagnosed	O
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O

This	O
observational	O
study	I:C1518527
analysed	O
data	O
from	O
French	B:C1556084
administrative	O
databases	I:C0242356
for	O
more	O
than	O
30,000	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
diagnosed	O
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O

This	O
observational	O
study	I:C1518527
analysed	O
data	O
from	O
French	O
administrative	B:C0242356
databases	I:C0242356
for	O
more	O
than	O
30,000	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
diagnosed	O
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O

This	O
observational	O
study	I:C1518527
analysed	O
data	O
from	O
French	O
administrative	O
databases	I:C0242356
for	O
more	O
than	O
30,000	O
patients	O
with	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
diagnosed	O
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O

This	O
observational	O
study	I:C1518527
analysed	O
data	O
from	O
French	O
administrative	O
databases	I:C0242356
for	O
more	O
than	O
30,000	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
diagnosed	B:C0011900
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O

The	O
incidence	O
of	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	O
departments	O
into	O
which	O
France	O
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	B:C0444454
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	O
departments	O
into	O
which	O
France	O
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	B:C0543467
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	O
departments	O
into	O
which	O
France	O
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	B:C0454828
regions	I:C0454828
and	O
95	O
French	O
departments	O
into	O
which	O
France	O
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	B:C1556084
departments	O
into	O
which	O
France	O
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	O
departments	B:C1704729
into	O
which	O
France	O
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	O
departments	O
into	O
which	O
France	B:C0016674
is	O
divided	O
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
incidence	O
of	O
hepatocellular	O
carcinoma	I:C2239176
,	O
access	O
to	O
surgery	O
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	I:C0454828
and	O
95	O
French	O
departments	O
into	O
which	O
France	O
is	O
divided	B:C2919030
administratively	I:C2919030
)	O
,	O
were	O
determined	O
.	O

The	O
influence	O
on	O
outcome	O
of	O
the	O
structure	O
of	O
the	O
hospital	B:C0019994
where	O
hepatocellular	O
carcinoma	I:C2239176
was	O
first	O
managed	O
was	O
assessed	O
.	O

The	O
influence	O
on	O
outcome	O
of	O
the	O
structure	O
of	O
the	O
hospital	O
where	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
was	O
first	O
managed	O
was	O
assessed	O
.	O

At	O
the	O
national	O
level	O
,	O
the	O
median	O
survival	O
was	O
9.4	O
months	O
and	O
only	O
22.8	O
%	O
of	O
patients	O
had	O
curative	B:C1273390
treatment	I:C1273390
.	O

There	O
were	O
marked	O
variations	O
between	O
regions	B:C0017446
and	O
departments	O
in	O
incidence	O
,	O
access	O
to	O
curative	O
treatment	I:C1273390
(	O
range	O
1.3-28.8	O
%	O
and	O
8.1	O
-32.3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	O
survival	O
(	O
range	O
5.7	O
-	O
12.1	O
and	O
4.3	O
-	O
16.5	O
months	O
respectively	O
)	O
.	O

There	O
were	O
marked	O
variations	O
between	O
regions	O
and	O
departments	B:C1704729
in	O
incidence	O
,	O
access	O
to	O
curative	O
treatment	I:C1273390
(	O
range	O
1.3-28.8	O
%	O
and	O
8.1	O
-32.3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	O
survival	O
(	O
range	O
5.7	O
-	O
12.1	O
and	O
4.3	O
-	O
16.5	O
months	O
respectively	O
)	O
.	O

There	O
were	O
marked	O
variations	O
between	O
regions	O
and	O
departments	O
in	O
incidence	O
,	O
access	B:C0444454
to	O
curative	O
treatment	I:C1273390
(	O
range	O
1.3-28.8	O
%	O
and	O
8.1	O
-32.3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	O
survival	O
(	O
range	O
5.7	O
-	O
12.1	O
and	O
4.3	O
-	O
16.5	O
months	O
respectively	O
)	O
.	O

There	O
were	O
marked	O
variations	O
between	O
regions	O
and	O
departments	O
in	O
incidence	O
,	O
access	O
to	O
curative	B:C1273390
treatment	I:C1273390
(	O
range	O
1.3-28.8	O
%	O
and	O
8.1	O
-32.3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	O
survival	O
(	O
range	O
5.7	O
-	O
12.1	O
and	O
4.3	O
-	O
16.5	O
months	O
respectively	O
)	O
.	O

The	O
administrative	O
type	O
and	O
annual	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
-	O
caseload	O
of	O
the	O
hospital	O
where	O
patients	O
were	O
first	O
admitted	O
also	O
had	O
an	O
independent	O
influence	O
on	O
treatment	O
and	O
survival	O
.	O

The	O
administrative	O
type	O
and	O
annual	O
hepatocellular	O
carcinoma	I:C2239176
-	O
caseload	O
of	O
the	O
hospital	B:C0019994
where	O
patients	O
were	O
first	O
admitted	O
also	O
had	O
an	O
independent	O
influence	O
on	O
treatment	O
and	O
survival	O
.	O

The	O
administrative	O
type	O
and	O
annual	O
hepatocellular	O
carcinoma	I:C2239176
-	O
caseload	O
of	O
the	O
hospital	O
where	O
patients	O
were	O
first	O
admitted	B:C0184666
also	O
had	O
an	O
independent	O
influence	O
on	O
treatment	O
and	O
survival	O
.	O

The	O
administrative	O
type	O
and	O
annual	O
hepatocellular	O
carcinoma	I:C2239176
-	O
caseload	O
of	O
the	O
hospital	O
where	O
patients	O
were	O
first	O
admitted	O
also	O
had	O
an	O
independent	O
influence	O
on	O
treatment	B:C0087111
and	O
survival	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	B:C0682134
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	O
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	O
carcinoma	I:C2239176
surveillance	O
and	O
management	O
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	O
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	B:C0376636
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	O
carcinoma	I:C2239176
surveillance	O
and	O
management	O
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	O
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	O
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
surveillance	O
and	O
management	O
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	O
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	O
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	O
carcinoma	I:C2239176
surveillance	B:C0038842
and	O
management	O
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	O
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	O
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	O
carcinoma	I:C2239176
surveillance	O
and	O
management	B:C0376636
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	O
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	O
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	O
carcinoma	I:C2239176
surveillance	O
and	O
management	O
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	B:C1273390
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	O
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
hepatocellular	O
carcinoma	I:C2239176
surveillance	O
and	O
management	O
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	O
treatment	I:C1273390
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	B:C0421454
.	O

The	O
hospital	B:C0019994
in	O
which	O
patients	O
are	O
first	O
managed	O
has	O
a	O
clear	O
influence	O
on	O
accessibility	O
to	O
both	O
good	O
care	O
and	O
survival	O
.	O

Population	B:C1709599
-	I:C1709599
based	I:C1709599
studies	I:C1709599
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	O
in	O
the	O
survival	O
of	O
patients	O
with	O
malignancy	O
.	O

Population	O
-	I:C1709599
based	I:C1709599
studies	I:C1709599
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	B:C0454664
in	O
the	O
survival	O
of	O
patients	O
with	O
malignancy	O
.	O

Population	O
-	I:C1709599
based	I:C1709599
studies	I:C1709599
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	O
in	O
the	O
survival	O
of	O
patients	O
with	O
malignancy	B:C4282132
.	O

As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	O
of	O
health	O
systems	O
,	O
in	O
addition	O
to	O
the	O
incidence	O
of	O
the	O
cancer	B:C0006826
or	O
quality	O
of	O
registration	O
,	O
variations	O
within	O
a	O
given	O
country	O
should	O
be	O
minimal	O
.	O

As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	O
of	O
health	O
systems	O
,	O
in	O
addition	O
to	O
the	O
incidence	O
of	O
the	O
cancer	O
or	O
quality	O
of	O
registration	B:C1514821
,	O
variations	O
within	O
a	O
given	O
country	O
should	O
be	O
minimal	O
.	O

As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	O
of	O
health	O
systems	O
,	O
in	O
addition	O
to	O
the	O
incidence	O
of	O
the	O
cancer	O
or	O
quality	O
of	O
registration	O
,	O
variations	O
within	O
a	O
given	O
country	B:C0454664
should	O
be	O
minimal	O
.	O

However	O
,	O
similar	O
to	O
between	O
countries	B:C0454664
differences	O
,	O
this	O
study	O
shows	O
differences	O
within	O
the	O
same	O
country	O
in	O
the	O
incidence	O
,	O
curative	O
treatment	I:C1273390
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
.	O

However	O
,	O
similar	O
to	O
between	O
countries	O
differences	O
,	O
this	O
study	B:C2603343
shows	O
differences	O
within	O
the	O
same	O
country	O
in	O
the	O
incidence	O
,	O
curative	O
treatment	I:C1273390
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
.	O

However	O
,	O
similar	O
to	O
between	O
countries	O
differences	O
,	O
this	O
study	O
shows	O
differences	O
within	O
the	O
same	O
country	B:C0454664
in	O
the	O
incidence	O
,	O
curative	O
treatment	I:C1273390
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
.	O

However	O
,	O
similar	O
to	O
between	O
countries	O
differences	O
,	O
this	O
study	O
shows	O
differences	O
within	O
the	O
same	O
country	O
in	O
the	O
incidence	O
,	O
curative	B:C1273390
treatment	I:C1273390
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
hepatocellular	O
carcinoma	I:C2239176
.	O

However	O
,	O
similar	O
to	O
between	O
countries	O
differences	O
,	O
this	O
study	O
shows	O
differences	O
within	O
the	O
same	O
country	O
in	O
the	O
incidence	O
,	O
curative	O
treatment	I:C1273390
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
.	O

Evidence	O
that	O
access	O
to	O
care	O
and	O
survival	O
varies	O
within	O
a	O
country	B:C0454664
can	O
strengthen	O
the	O
impetus	O
for	O
government	O
and	O
clinicians	O
to	O
address	O
these	O
disparities	O
.	O

Evidence	O
that	O
access	O
to	O
care	O
and	O
survival	O
varies	O
within	O
a	O
country	O
can	O
strengthen	O
the	O
impetus	O
for	O
government	B:C0018104
and	O
clinicians	O
to	O
address	O
these	O
disparities	O
.	O

Evidence	O
that	O
access	O
to	O
care	O
and	O
survival	O
varies	O
within	O
a	O
country	O
can	O
strengthen	O
the	O
impetus	O
for	O
government	O
and	O
clinicians	B:C0871685
to	O
address	O
these	O
disparities	O
.	O

